Eli Lilly and Company (NYSE:LLY) Stock Price Up 1.6% - What's Next?

Key Points

• Eli Lilly's stock price increased by 1.6%, reaching $812.33, with a significant trading volume drop of 28% from its average.
• Analysts have varied opinions on Eli Lilly, with prices ranging from a low of $715 to a high of $900; the consensus rating is a "Moderate Buy" with a target price of $938.61.
• The company reported earnings per share of $6.31, beating estimates and reflecting a 37.6% revenue increase year-over-year, with current guidance for FY 2025 set between 21.750 and 23.000 EPS.

Eli Lilly and Company (NYSE:LLY - Get Free Report) shares rose 1.6% during mid-day trading on Wednesday . The stock traded as high as $815.94 and last traded at $812.33. Approximately 2,919,094 shares traded hands during mid-day trading, a decline of 28% from the average daily volume of 4,036,808 shares. The stock had previously closed at $799.57.

Analyst Ratings Changes

LLY has been the subject of several research reports. The Goldman Sachs Group upped their target price on Eli Lilly and Company from $876.00 to $879.00 and gave the stock a "buy" rating in a research note on Friday, October 10th. Leerink Partners reiterated a "market perform" rating and issued a $715.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Deutsche Bank Aktiengesellschaft lowered their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating for the company in a research report on Monday, August 11th. DZ Bank upgraded Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 14th. Finally, Guggenheim reiterated a "buy" rating and issued a $948.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, October 16th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and a consensus price target of $938.61.

Eli Lilly and Company Stock Performance

The company has a market capitalization of $768.84 billion, a PE ratio of 53.09, a PEG ratio of 1.16 and a beta of 0.47. The company has a 50 day moving average of $759.77 and a two-hundred day moving average of $766.43. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion for the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm's revenue for the quarter was up 37.6% on a year-over-year basis. During the same period in the prior year, the firm earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Jamere Jackson purchased 200 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, August 8th. The shares were bought at an average cost of $639.56 per share, with a total value of $127,912.00. Following the completion of the purchase, the director directly owned 9,402 shares in the company, valued at approximately $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Daniel Skovronsky purchased 1,000 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the purchase, the executive vice president owned 137,660 shares of the company's stock, valued at $87,331,504. This trade represents a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought 4,514 shares of company stock valued at $2,894,841 over the last 90 days. 0.14% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Eli Lilly and Company

A number of institutional investors have recently modified their holdings of the stock. Hobbs Wealth Management LLC grew its stake in shares of Eli Lilly and Company by 0.8% in the first quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company's stock worth $1,205,000 after acquiring an additional 12 shares during the last quarter. Hixon Zuercher LLC grew its stake in shares of Eli Lilly and Company by 0.7% in the first quarter. Hixon Zuercher LLC now owns 1,789 shares of the company's stock worth $1,477,000 after acquiring an additional 12 shares during the last quarter. O Brien Wealth Partners LLC grew its stake in shares of Eli Lilly and Company by 25.5% in the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock worth $49,000 after acquiring an additional 12 shares during the last quarter. Ascent Capital Management LLC grew its stake in shares of Eli Lilly and Company by 2.5% in the first quarter. Ascent Capital Management LLC now owns 495 shares of the company's stock worth $409,000 after acquiring an additional 12 shares during the last quarter. Finally, Willner & Heller LLC grew its stake in shares of Eli Lilly and Company by 1.5% in the first quarter. Willner & Heller LLC now owns 854 shares of the company's stock worth $705,000 after acquiring an additional 13 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.